glp-1 contraindications Benefits and Risks of Receptor Agonists Outlined GLP-1 Receptor Agonists for Obesity

Cell, 153(6), 11941217

8 Based on data from the MAESTRO-NASH trial, resmetirom demonstrated histological benefits with a number needed to treat of five for the resolution of MASH and 8.5 for fibrosis regression, 9 thus posing significant economic challenges

Leggio L et al

Contrave (naltrexone/bupropion) has demonstrated effectiveness for long-term weight loss when used in conjunction with a reduced-calorie diet and regular exercise

Its production cost and price are also key to determining whether the drug can be used by American insurers and the European health care system

Coinsurance and copays depend on how Ozempic is labeled in the plans drug formulary